Targovax has the cheapest oncolytic virus on the market
ONCOS-102 is one of the most promising oncolytic viruses with >200 patients treated.
Targovax stock has been under pressure for years after equity offerings at fairly low pricing, but has been making a strong move recently, quite without many investors taking notice.
Norwegian Biotech especially in the field of cancer immunotherapy may be ready for a new round of interest after the recent news about Vaccibody partnering with Genentech.
Targovax stock has been under pressure for years after equity offerings at fairly low pricing, but has been making a strong move recently, quite without many investors taking notice.
Norwegian Biotech especially in the field of cancer immunotherapy may be ready for a new round of interest after the recent news about Vaccibody partnering with Genentech.
トレード稼働中:
Positive news last night from Targovax, webcast in 30 minutes from now
Targovax announces impressive objective responses as well as effects on non-injected lesions in ONCOS-102 trial in anti-PD1 refractory melanoma patients
· Tumor responses observed in 7 out of 20 evaluable patients, resulting in best
objective response rate (ORR) of 35%
· Systemic effects observed in multiple patients, including two examples where
a non-injected lesion completely regressed
· An online presentation by Targovax's management will take place at 10:00 CET
2 December 2020 (details below)
Targovax announces impressive objective responses as well as effects on non-injected lesions in ONCOS-102 trial in anti-PD1 refractory melanoma patients
· Tumor responses observed in 7 out of 20 evaluable patients, resulting in best
objective response rate (ORR) of 35%
· Systemic effects observed in multiple patients, including two examples where
a non-injected lesion completely regressed
· An online presentation by Targovax's management will take place at 10:00 CET
2 December 2020 (details below)
トレード稼働中:
Nice bounce today, stay in the trade
トレード稼働中:
Targovax received FDA Fast track designation for Oncos 102!
Stay in trade.
Stay in trade.
